Core Viewpoint - Evommune (EVMN.US) has successfully entered the US stock market, experiencing a price increase of over 15%, currently trading at $18.38, with an IPO price set at $16 [1] Company Overview - Evommune is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of immune-mediated chronic inflammatory diseases [1] - The diseases targeted by Evommune include chronic urticaria, atopic dermatitis, and other conditions related to mast cells and inflammation [1]